IDH1 and IDH2 inhibitors, such as ivosidenib and enasidenib, have demonstrated efficacy in patients with relapsed or refractory IDH1- or IDH2-mutated AML [4,13]. Here, IDH2 is linked to acute myeloid leukemia.